These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31383252)

  • 61. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 62. LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.
    Chang EES; Ho PW; Liu HF; Pang SY; Leung CT; Malki Y; Choi ZY; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Feb; 11(1):10. PubMed ID: 35152914
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson's disease.
    Rivero-Ríos P; Gómez-Suaga P; Fernández B; Madero-Pérez J; Schwab AJ; Ebert AD; Hilfiker S
    Biochem Soc Trans; 2015 Jun; 43(3):390-5. PubMed ID: 26009181
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
    Fernández B; Lara Ordóñez AJ; Fdez E; Mutez E; Comptdaer T; Leghay C; Kreisler A; Simonin C; Vandewynckel L; Defebvre L; Destée A; Bleuse S; Taymans JM; Chartier-Harlin MC; Hilfiker S
    Biochem J; 2019 Oct; 476(19):2797-2813. PubMed ID: 31527116
    [TBL] [Abstract][Full Text] [Related]  

  • 66. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.
    Chen ML; Wu RM
    J Biomed Sci; 2018 Jun; 25(1):52. PubMed ID: 29903014
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
    Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
    Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.
    Bae JR; Lee BD
    BMB Rep; 2015 May; 48(5):243-8. PubMed ID: 25703537
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synthesis and Preliminary Evaluation of [
    Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
    ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
    [TBL] [Abstract][Full Text] [Related]  

  • 71. LRRK2 Phosphorylation: Behind the Scenes.
    De Wit T; Baekelandt V; Lobbestael E
    Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
    [TBL] [Abstract][Full Text] [Related]  

  • 72. LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis.
    Volta M; Melrose H
    Biochem Soc Trans; 2017 Feb; 45(1):113-122. PubMed ID: 28202664
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 74. LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8.
    Fais M; Sanna G; Galioto M; Nguyen TTD; Trần MUT; Sini P; Carta F; Turrini F; Xiong Y; Dawson TM; Dawson VL; Crosio C; Iaccarino C
    Cells; 2021 Jan; 10(2):. PubMed ID: 33498474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
    Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
    [TBL] [Abstract][Full Text] [Related]  

  • 77. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
    Outeiro TF; Harvey K; Dominguez-Meijide A; Gerhardt E
    Biochem Soc Trans; 2019 Jun; 47(3):827-838. PubMed ID: 31085616
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Small-Molecule Inhibitors of LRRK2.
    Hatcher JM; Choi HG; Alessi DR; Gray NS
    Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.
    Baidya AT; Deshwal S; Das B; Mathew AT; Devi B; Sandhir R; Kumar R
    Bioorg Chem; 2024 Feb; 143():106972. PubMed ID: 37995640
    [TBL] [Abstract][Full Text] [Related]  

  • 80. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.